Buttarelli et al. [52] generated a ten-gene signature, including the downregulated GNG11 gene, that predicts response to first-line chemotherapy in high-grade serous ovarian cancer patients. This evidence concerns the gene GNG11 and ovarian serous adenocarcinoma.